NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial

Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.

Zacks Investment Research • Jun 1, 2026

Why Natera Is My Favorite Stock Idea for the Rest of 2026

It's hard to pick just one favorite stock idea for the rest of the year. It's been a blistering-hot 2026, as the AI revolution keeps rolling ahead.

24/7 Wall Street • May 29, 2026

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos' DOC-RM Phase I/II investigational immunotherapy.

Business Wire • May 29, 2026

Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions

NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.

Zacks Investment Research • May 28, 2026

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer. The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combination with endocrine therapy for patients with intermediat.

Business Wire • May 28, 2026

Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results

Natera gets buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue guidance. NTRA's Q1 revenue grew 38% YoY, with test volumes up 18.5%, reflecting strong operational momentum and market demand. Despite ongoing unprofitability, margin improvements and analyst consensus point toward profitability by FY28, supported by upward earnings revisions.

Seeking Alpha • May 27, 2026

Baron Health Care Fund Q1 2026 Portfolio Activity

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Seeking Alpha • May 27, 2026

Natera Expands Austin Operations With New Sequencing Facility

NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.

Zacks Investment Research • May 26, 2026

Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company's novel SNP-informed deep sequencing technology, Panorama NIPT is now backed by clinically-validated performance data in samples with low fetal fraction, enabling a no-call rate of 0.5%. Fetal fraction refers to the proportion of placental DNA circulating.

Business Wire • May 26, 2026

Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone

NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.

Zacks Investment Research • May 21, 2026